Belite Bio Submits Tinlarebant Applications in Three Markets for Rare Eye Disease

04:33 PM EDT, 10/14/2026 (MT Newswires) -- Belite Bio (BLTE) has submitted marketing authorization applications in Singapore, the UK and Switzerland for tinlarebant, an investigational treatment for Stargardt disease type 1, it said Wednesday. STGD1 is a rare retinal disease caused due to mutations in the ABCA4 gene that leads to progressive and irreversible loss of vision, according to a statement. The submissions follow accepted new drug applications in the US and Japan, the company said, adding that the US application has a Prescription Drug User Fee Act target action date of Feb. 12, 2027.